
After the U.S. and Europe, Japan holds the largest share for TAVI devices. The large population of elderly above the age of 65 years with aortic stenosis, high adoption of TAVI devices for the treatment of aortic stenosis, and favorable reimbursement policies in the country are expected to further drive the market growth. Furthermore, companies have been modifying the TAVR devices according to the needs of patients, for instance, in 2013, Edwards Lifesciences developed smallest-sized version of its SAPIEN XT TAVI valve, which is ideal for Japanese patients.